Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

In May 2025, The Handmaid’s Tale concluded its six-season run on television. The final episode closed the stories of several main characters who lived under the rule of Gilead, a strict regime that ...